<DOC>
	<DOCNO>NCT00129519</DOCNO>
	<brief_summary>The primary objective study ass whether basal cell carcinoma ( BCC ) lesion surgically treat curettage , follow imiquimod 5 % cream postsurgical adjuvant therapy , improved cure rate ED/C historical norm approximately 70 % 1-year posttreatment follow-up . A secondary objective ass cosmetic outcome .</brief_summary>
	<brief_title>A Study Evaluate Effectiveness Imiquimod 5 % Cream Basal Cell Carcinoma Recurrence</brief_title>
	<detailed_description>This open-label , phase IIIb , multicenter , single arm , historical-controlled study . Biopsy-confirmed BCC lesion ( 1 per subject ) excise curettage , electrodessication . Approximately 1 week later , treatment imiquimod 5 % cream initiate . Imiquimod apply target BCC daily , 5 time per week ( 5x/week ) 6 week . Rest period allow need . Subjects report study center treatment week 1 , 2 , 6 , posttreatment week 12 , 26 , 52 . At treatment week 6 posttreatment visit , investigator clinically assess target site tumor clearance cosmetic outcome . A template make initiation create clear plastic overlay aid locate target tumor site . If investigator identify lesion occur recurred target site , subject discontinue study count recurrence/persistence ( R/P ) .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Carcinoma , Basal Cell</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<criteria>Basal cell carcinoma Psoriasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>BCC curettage</keyword>
</DOC>